|Day Low/High||147.85 / 150.40|
|52 Wk Low/High||101.36 / 170.75|
Successful tests of a rising 200-day moving average line can be great entry points for longs.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Do these shares get back to the 2020 highs that were reached back in January?
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
Potential for a new blockbuster breast cancer treatment is eyed as possible game changer, so let's see the charts and indicators for a new target.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
The question is whether you want to buy before the breakout or after the breakout?
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
Here are my thoughts on the quarter and trading the stock.
Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.
Our technical strategy says that Eli Lilly can be bought on strength over $144, as the name looks more attractive along with others in the health care sector.
These pharmaceutical names have what it takes amid the current crisis and for the long run.
LLY is entering into a new partnership with AbCellera Biologics in an attempt to develop an antibody for Covid-19.
The answer to that question depends on several factors, so let's break them down.
It's no secret that the Fed would like to get out of the short-term repo business.
Here's my strategy which has worked particularly well.
It is nice to once again be sitting in for Doug Kass this Friday at the Daily Diary. I will be coming to you from a Starbucks in downtown Miami this morning, as the internet in my building has decided to opt for a three-day weekend. Oh, the perils o...
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
These healthcare stalwarts look attractive for growth and income.